Fiche centre
TG Therapeutics Investigational Trial Site
Olsztyn — Poland
Essais liés3clinical trials
VilleOlsztynlocalisation
PaysPolandlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07503873
Essais cliniques associés
3| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Ublituximab | SEP | Phase 2 | NCT07503873 | A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS) | RECRUITING |
| Ublituximab | SEP | Phase 3 | NCT05877963 | ENHANCE — Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | RECRUITING |
| Ublituximab | SEP | Phase 3 | NCT04130997 | An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis | ACTIVE_NOT_RECRUITING |